Reach Us +44-1764-910199
Editor - Dr.Sanjib Bhakta | University of London | 5744
ISSN: 2168-9547

Molecular Biology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Dr.Sanjib Bhakta

Dr.Sanjib Bhakta
Sanjib Bhakta
Senior Lecturer
Department of Microbiology
University of London
University of London


Dr. Sanjib Bhakta is a Senior Lecturer in Microbiology at Birkbeck, University of London. His continued research interestis focussedon developing novel therapeutics to tacklepersistence and drug resistance in Tuberculosis. Following aBSc(Hons), an MSc and a PhD in Molecular Biology & Biochemistry in India, Dr Bhakta joined the Oxford University as an ISIS innovation Senior Research Scholar anda Wellcome Trust International Travelling Fellow. He graduated from The Queen’s College, University of Oxford completing a DPhiland received a “Sir William Paton Prize” for the best research presentation in Pharmacology. He joined Birkbeck as a University Lecturerand became a Fellow of the Higher Education Academy, UK after achieving a post graduate certificate in Teaching and Life Long Learning in Higher Education (PGCHE) from the University of London. He is a core memberof Tuberculosis Drug Discovery-UK, the Institute of Structural and Molecular Biologyand an affiliated Fellow of the Centre for Infection, Immunity and Disease Mechanism. He is an electedFellow of the Royal Society of Medicine and a Chartered Biologist in the UK.

Research Interest

The disease Tuberculosis (TB), once considered eradicated has now become a major global health concern. It is a condition that, if untreated, can last for several years during which patients are debilitated and may disseminate the causal pathogen, Mycobacterium tuberculosis. We characterise the structure, function, regulation and inhibition of key biochemical pathways in mycobacteriato identify and validate potential therapeutic targets in M. tuberculosisas well as to facilitate the development of a new drug treatment against the different physiological stages of M. tuberculosis infection.



Global Speakers in the subject

Global Experts in the subject